** **
Home / Disease prevention / New guidelines for prostate cancer patients
alibaba.com, cpa campaign, lead generation, lead campaign, smart match lander, intelligent lander, a

New guidelines for prostate cancer patients

Not everyone is a candidate for the PSA test and screening for prostate cancer is not clear-cut.
Prostate cancer screening made headlines recently because of a change in the recommendations about the prostate-specific antigen test.
Some studies have found that 1 in every 70 men who undergo radiation therapy for prostate cancer or presumed prostate cancer will develop a secondary cancer such as sarcoma or leukemia.
The older recommendation said the PSA test “has no net benefit or that the harms outweigh the benefits.”The new guidelines released April 11 tell a different story.
The U.S. Preventive Services Task Force now suggests there is evidence that the PSA test provides a small benefit — for some men.

prostate cancer symptom

according to

What you should know about prostate cancer

In recent years, the U.S. Food and Drug Administration has approved six drugs for men with metastatic prostate cancer that increase survival.
April 18 (UPI) — New combination therapy identified that may do more than just extend survival but could cure metastatic prostate cancer.
Researchers have gone a step further and shown an aggressive combination of systemic therapy or drug treatment combined with local therapy, including surgery and radiation, targeting the primary tumor and metastasis can kill all detectable disease in certain patients with metastatic prostate cancer.
Fourteen patients, or 93 percent, reached an undetectable PSA when ADT, surgery and radiation were used.
Four of the patients extra-pelvic lymph node involvement, achieved an undetectable PSA after ADT and surgery.
This content may collect you by Sydney Connor

Check Also

Nervous Breakdown symptoms

Top 10 Nervous Breakdown signs and symptoms

When Nervous Breakdown signs and Symptoms of nervous breakdown appear on someone, it means that they …